Advanced search
1 file | 1.57 MB Add to list

Quality standards in respiratory real-life effectiveness research : the REal Life EVidence AssessmeNt Tool (RELEVANT) : report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force

Author
Organization
Abstract
Introduction: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development. Methods: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness. Results: Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers. Conclusions: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice.
Keywords
Asthma, Comparative effectiveness, Quality standards, Observational studies, Database, RETROSPECTIVE DATABASE ANALYSIS, RANDOMIZED CONTROLLED-TRIALS, COPD GUIDELINE DEVELOPMENT., SECONDARY DATA SOURCES, INHALED CORTICOSTEROIDS, ASTHMA CONTROL, COORDINATING EFFORTS, COST-EFFECTIVENESS, PERSISTENT ASTHMA, ADHERENCE

Downloads

  • Roche2019 Article QualityStandardsInRespiratoryR.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.57 MB

Citation

Please use this url to cite or link to this publication:

MLA
Roche, Nicolas, et al. “Quality Standards in Respiratory Real-Life Effectiveness Research : The REal Life EVidence AssessmeNt Tool (RELEVANT) : Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force.” CLINICAL AND TRANSLATIONAL ALLERGY, vol. 9, 2019.
APA
Roche, N., Campbell, J. D., Krishnan, J. A., Brusselle, G., Chisholm, A., Bjermer, L., … Price, D. (2019). Quality standards in respiratory real-life effectiveness research : the REal Life EVidence AssessmeNt Tool (RELEVANT) : report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force. CLINICAL AND TRANSLATIONAL ALLERGY, 9.
Chicago author-date
Roche, Nicolas, Jonathan D Campbell, Jerry A Krishnan, Guy Brusselle, Alison Chisholm, Leif Bjermer, Mike Thomas, et al. 2019. “Quality Standards in Respiratory Real-Life Effectiveness Research : The REal Life EVidence AssessmeNt Tool (RELEVANT) : Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force.” CLINICAL AND TRANSLATIONAL ALLERGY 9.
Chicago author-date (all authors)
Roche, Nicolas, Jonathan D Campbell, Jerry A Krishnan, Guy Brusselle, Alison Chisholm, Leif Bjermer, Mike Thomas, Eric van Ganse, Maarten van den Berge, George Christoff, Jennifer Quint, Nikolaos G Papadopoulos, and David Price. 2019. “Quality Standards in Respiratory Real-Life Effectiveness Research : The REal Life EVidence AssessmeNt Tool (RELEVANT) : Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force.” CLINICAL AND TRANSLATIONAL ALLERGY 9.
Vancouver
1.
Roche N, Campbell JD, Krishnan JA, Brusselle G, Chisholm A, Bjermer L, et al. Quality standards in respiratory real-life effectiveness research : the REal Life EVidence AssessmeNt Tool (RELEVANT) : report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force. CLINICAL AND TRANSLATIONAL ALLERGY. 2019;9.
IEEE
[1]
N. Roche et al., “Quality standards in respiratory real-life effectiveness research : the REal Life EVidence AssessmeNt Tool (RELEVANT) : report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force,” CLINICAL AND TRANSLATIONAL ALLERGY, vol. 9, 2019.
@article{8632766,
  abstract     = {{Introduction: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development.
Methods: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness.
Results: Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers.
Conclusions: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice.}},
  articleno    = {{20}},
  author       = {{Roche, Nicolas and Campbell, Jonathan D and Krishnan, Jerry A and Brusselle, Guy and Chisholm, Alison and Bjermer, Leif and Thomas, Mike and van Ganse, Eric and van den Berge, Maarten and Christoff, George and Quint, Jennifer and Papadopoulos, Nikolaos G and Price, David}},
  issn         = {{2045-7022}},
  journal      = {{CLINICAL AND TRANSLATIONAL ALLERGY}},
  keywords     = {{Asthma,Comparative effectiveness,Quality standards,Observational studies,Database,RETROSPECTIVE DATABASE ANALYSIS,RANDOMIZED CONTROLLED-TRIALS,COPD GUIDELINE DEVELOPMENT.,SECONDARY DATA SOURCES,INHALED CORTICOSTEROIDS,ASTHMA CONTROL,COORDINATING EFFORTS,COST-EFFECTIVENESS,PERSISTENT ASTHMA,ADHERENCE}},
  language     = {{und}},
  pages        = {{17}},
  title        = {{Quality standards in respiratory real-life effectiveness research : the REal Life EVidence AssessmeNt Tool (RELEVANT) : report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force}},
  url          = {{http://dx.doi.org/10.1186/s13601-019-0255-x}},
  volume       = {{9}},
  year         = {{2019}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: